** Shares of Telix Pharmaceuticals rise as much as 7.4% to A$25.79, their biggest gain since Sept. 20, 2024
** Stock hits highest level since Dec. 18, 2024 ** The biopharmaceutical co records revenue of $517 mln in FY, beating its forecast of $490 mln to $510 mln
** Co reports 55% y-o-y growth in full-year revenue ** Stock is among the top 10 performers on ASX 200 benchmark
** Shares gained 144.1% in 2024
(Reporting by Jasmeen Ara Shaikh in Bengaluru) ((mailto:Jasmeenaraislam.shaikh@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。